Clinical Trials Logo

Gastro-esophageal Reflux Disease clinical trials

View clinical trials related to Gastro-esophageal Reflux Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05296655 Completed - Clinical trials for Gastro Esophageal Reflux Disease

Kazakh Version of Reflux Symptom Index

Start date: March 1, 2020
Phase:
Study type: Observational

Reflux symptoms index (RSI) were developed to identify a clinical index of suspicion for laryngopharyngeal reflux (LPR) in patients with ear, nose, and throat symptoms. RSI is an efficient diagnostic tool for LPR/ It is easy to use, even for those who know little about LPR. It does not require special equipment or examinations and is inexpensive. Thus, it can be considered highly efficient and cost-effective. The study will focus on translating and testing the RSI into Kazakh language and comparing its results in healthy people and people with laryngopharyngeal reflux.

NCT ID: NCT04988347 Completed - Dyspepsia Clinical Trials

Spirulina Platensis for PPI Withdrawal

SpAReDPPI
Start date: November 2010
Phase: Phase 2
Study type: Interventional

Background: Rebound acid hypersecretion after proton pump inhibitors (PPIs) discontinuation may be accompanied by dyspepsia. Aim: To assess whether Spirulina platensis, by its anti-inflammatory properties, could minimize rebound symptoms after PPIs withdrawal.

NCT ID: NCT03788109 Completed - Clinical trials for Functional Dyspepsia

Relationship Between Gastric Accommodation, TLESRs and Reflux in HV and in GERD With or Without Overlapping Dyspepsia

Start date: June 12, 2018
Phase: N/A
Study type: Interventional

Our group recently studied the relationship between intra-gastric pressure (IGP) and reflux events after a meal, both in gastro-esophageal reflux disease (GERD) and in healthy volunteers (HV). Ingestion of a meal was accompanied by a drop in IGP, probably representing gastric accommodation (GA). However, the magnitude of this IGP drop varied, and was inversely correlated with the number of transient lower esophageal sphincter relaxations (TLESRs) and the number of reflux events, both in patients and in HV: a smaller meal-induced drop in IGP was associated with a higher rate of reflux events, and vice versa. These findings suggest that impaired GA is a trigger for reflux. Furthermore, impaired GA is a well-established mechanism underlying symptom generation in functional dyspepsia (FD). Hence, the investigators hypothesize that impaired GA is an important pathophysiological feature explaining the overlap between GERD and FD. To evaluate this hypothesis, the investigators will study the relationship between GA, TLESRs and reflux events in HV and in a group of GERD patients which will be categorized as pure GERD or GERD/FD overlap.

NCT ID: NCT03322553 Completed - Clinical trials for Gastro Esophageal Reflux Disease

Endoscopic Full Thickness Plication (GERD-X) for the Treatment of PPI Dependent GERD:

Start date: November 15, 2017
Phase: N/A
Study type: Interventional

Gastro-esophageal reflux disease (GERD) is a common gastrointestinal disorder with a significant proportion of patients becoming dependent on proton pump inhibitor (PPI) therapy. Long term use of PPI therapy can be associated with side effects such as osteoporosis, small intestinal bacterial overgrowth and renal failure. Moreover, some of the patients might be reluctant to take PPIs for long duration and prefer surgery over pharmacotherapy. Endoscopic plication (GERD-X) is an alternative and less invasive procedure compared to laparoscopic fundoplication for the treatment of GERD. In endoscopic plication, transmural sutures are applied at the gastro-esophageal (GE) junction thereby reconstructing the gastric cardia and accentuating the valvular mechanism to prevent reflux. Only few trials have evaluated the efficacy of endoscopic plication technique and reported encouraging results. In this study we aim to evaluate the efficacy of a similar endoscopic technique but with application of two transmural sutures in randomized controlled method.

NCT ID: NCT02456779 Completed - Clinical trials for Gastro-esophageal Reflux Disease

Validation of a Non-invasive In-vitro Diagnostic Test (Peptest) Against Other Diagnostic Methods for GERD

PEPTESTCN
Start date: May 2015
Phase: N/A
Study type: Observational

The primary objective of this clinical study is to determine whether Peptest (Human Pepsin lateral flow in vitro diagnostic medical device) is equivalent to other GERD diagnostic methods commonly applied in clinical practice by testing a large number of clinical samples. This will be performed by evaluating Peptest results in GERD patients (Erosive esophagitis or NERD), defined using standard clinical procedures, and compared to healthy controls.

NCT ID: NCT02114216 Completed - Clinical trials for Gastro-esophageal Reflux Disease

Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease

Start date: March 2013
Phase: N/A
Study type: Interventional

Transient receptor potential vanilloid-1 (TRPV1) receptor and proteinase-activated receptor 2 (PAR2) have been implicated in the mechanism of acid induced inflammation in gastroesophageal reflux disease (GERD). We aimed to evaluate TRPV1 and PAR2 mRNA expression levels in the GERD patients and their relationship with endoscopic findings and reflux symptoms.

NCT ID: NCT01867931 Completed - Clinical trials for Gastro-esophageal Reflux Disease

Epithelial Damage in GERD

Start date: April 2013
Phase: N/A
Study type: Observational

The purpose of this study is to characterize and compare epithelial damage in patients with erosive esophagitis and non-erosive reflux disease.

NCT ID: NCT01560910 Completed - Clinical trials for Non-erosive Reflux Disease

Detection of Minimal Change Esophagitis by I-scan

Start date: January 2010
Phase: N/A
Study type: Observational

Study design and objective The primary outcome of this prospective cohort study was to identify the endoscopic findings that have diagnostic value for the prediction of NERD (minimal change esophagitis) by using HD endoscopy with i-scan. The secondary outcome was to evaluate the response to proton pump inhibitor (PPI) in GERD patients with or without minimal change esophagitis.

NCT ID: NCT01503476 Completed - Clinical trials for Gastro Esophageal Reflux Disease

Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance

Start date: February 2012
Phase: Phase 4
Study type: Interventional

Study Hypothesis: This study is designed as an integral part of the development of new or improved features or components of the Bravo® pH Monitoring System and may serve verification and validation purposes The study population will include a group of healthy volunteers (Group A) and a group of symptomatic patients with known or suspected gastroesophageal reflux disease (Group B). Group A: Healthy volunteers will not undergo invasive procedure. These volunteers may be asked to carry the capsule and\or Bravo Recorder. These procedures will serve to evaluate different technical matters such as human interface, ergonomic aspects and communication performances of the system Group B: Symptomatic patients will undergo invasive procedure, including Bravo capsule delivery, positioning and attachment. Confirmation of capsule attachment may be done by endoscopically. These procedures will serve to evaluate overall system performance in actual clinical setup, for instance: Bravo Recorder performance including communication quality, human interface and similar, ergonomics of delivery device, pH Capsule performance, etc. Subjects from both study groups as well as physician may be asked to provide feedback on the procedure and/or document their activities during the procedure.